ClinicalTrials.gg
CompletedNCT04727021Updated Jan 27, 2021

A Trial to Learn How Much Rivaroxaban Gets Into the Blood When Taken in Different Forms and How Safe They Are in Healthy Men

A Phase 1 interventional study of 20 mg tablet rivaroxaban and 20 mg rivaroxaban, granules for oral suspension in Healthy Volunteers, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Bayer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years 6 months after the study started (first participant enrolled Jul 2017, registered Jan 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

Researchers are looking for a better way to treat venous thromboembolic disease, also known as VTE. In people with VTE, blood clots form in the veins of the legs, groin, or arms. These clots or a piece of a clot can break free and move around the body in the blood vessels. These clots can block small blood vessels, causing other conditions like high blood pressure, heart attack, and stroke.

Before people with a medical condition can take an approved treatment in a new form, researchers do trials in healthy participants. This helps them understand how the new form acts in the body and to better understand its safety.

In this trial, the researchers will compare how much of the trial treatment gets into the blood when taken in 2 different forms in a small number of participants. The trial will include about 30 men who are aged 18 to 55.

In this trial, there will be 2 groups of participants. The participants will take rivaroxaban in the current tablet form and in a new liquid form 1 time. This was a "crossover" trial. In a crossover trial, all the participants will take both forms of the treatments, but in a different order.

During the trial, the participants will stay at their trial site 2 times for 5 days. But, the participants can be in the trial for up to about 6 weeks. During the trial, the doctors will take blood and urine samples and check the participants' heart health using an electrocardiogram (ECG) and measure the blood pressure. The participants will also answer questions about how they are feeling, if they have any medical problems, and about any medications they are taking.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects.
  • Age: 18 to 55 years (inclusive) at the screening examination/visit.
  • Race: White (Note: Clinical Data Interchange Standards Consortium definition of White: Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White (Food and Drug Administration [FDA]).
  • (BMI): above/equal 18 and below/equal 29.9 kg/m2.
  • Ability to understand and follow instructions.

Exclusion criteria

Exclusion Criteria:

  • Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination and effects of the study drugs will not be normal
  • Known or suspected liver disorders and bile secretion/flow
  • Subjects with thyroid disorders as evidenced by assessment of thyroid stimulating hormone (TSH) levels outside the normal reference range at screening
  • Personal or familial history of genetically muscular diseases
  • Known to the study drugs (active substances or of the preparations)
  • Known severe allergies e.g. allergies to more than 3 allergens, allergies affecting the lower respiratory tract- allergic asthma, allergies requiring therapy with , urticaria) or significant non-allergic drug reactions
  • Known disorders with increased bleeding risk (e.g., periodontosis, hemorrhoids, acute gastritis, peptic ulcer)
  • Known sensitivity to common causes of bleeding (e.g. nasal)
  • findings in the (ECG) such as a second- or third-degree atrioventricular (AV) block, prolongation of the QRS (QRS interval in ECG) complex over 120 msec or of the -interval over 450 msec at the first screening visit
  • Presence or history of arrhythmic disturbances; or known congenital QT (QT interval in ECG) prolongation
  • Systolic blood pressure below 100 or above 140 mmHg
  • Diastolic blood pressure below 50 or above 90 mmHg
  • Heart rate below 50 or above 90 beats/ min
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment A: Single oral dose of a 20 mg tablet rivaroxaban

    2-way crossover: The subjects will receive the following treatments in a randomized order: * Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions * Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.

    Drug: 20 mg tablet rivaroxaban

  • Experimental
    Treatment B: Single oral dose of 20 mg rivaroxaban, granules

    2-way crossover: The subjects will receive the following treatments in a randomized order: * Treatment A: Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions * Treatment B: Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.

    Drug: 20 mg rivaroxaban, granules for oral suspension

Interventions

  • Drug20 mg tablet rivaroxaban

    Single oral dose of a 20 mg tablet rivaroxaban, administered under fed conditions

  • Drug20 mg rivaroxaban, granules for oral suspension

    Drug page: Rivaroxaban

    Single oral dose of 20 mg rivaroxaban, granules for oral suspension administered under fed conditions.

06

What researchers measure

Primary outcomes

  1. AUC of rivaroxaban granules for oral suspension vs. rivaroxaban tablet

    AUC = area under the concentration vs. time curve from zero to infinity after single (first) dose Rivaroxaban Blood sampling for rivaroxaban pharmacokinetics in plasma.

    Time frame: From pre-dose up to 72 hours after drug administration

  2. AUC(0-tlast) of rivaroxaban granules for oral suspension vs. rivaroxaban tablet

    AUC(0-tlast) = AUC from time 0 to the last data point \> lower limit of quantification (LLOQ) Rivaroxaban Blood sampling for rivaroxaban pharmacokinetics in plasma.

    Time frame: From pre-dose up to 72 hours after drug administration

  3. Cmax of rivaroxaban granules for oral suspension vs. rivaroxaban tablet

    Cmax = maximum observed drug concentration in measured matrix after single dose administration Rivaroxaban Blood sampling for rivaroxaban pharmacokinetics in plasma.

    Time frame: From pre-dose up to 72 hours after drug administration.

Secondary outcomes

  1. Number of treatment-emergent adverse events

    Adverse events occurring in the period between the signing of the informed consent and the end of the follow-up phase.

    Time frame: Up to 7-14 days after the last administration

07

Study locations

1 site
  • CRS Clinical-Research-Services Mönchengladbach GmbH
    Mönchengladbach, Nordrhein-Westfalen 41061, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2017 to primary completion in Sep 2017, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2021
First posted
Jan 27, 2021
StartActual
Jul 4, 2017
Primary completionActual
Sep 4, 2017
CompletionActual
Oct 27, 2017
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04727021
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 27, 2021
Start date
Jul 4, 2017
Primary completion
Sep 4, 2017
Completion
Oct 27, 2017
Last update
Jan 27, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion